
- Sex, Lies, and Pharmaceuticals: How Drug Companies Plan to Profit from Female Sexual Dysfunction
-
Amazon
From $15.95 (New)

From $15.95 (New)

| Latest | $15.95 Apr 16, '16 |
| Highest | $16.49 Feb 2, '16 |
| Lowest | $15.95 Apr 16, '16 |
| Average | $16.13 (30d avg) $16.24 (Lifetime average) |
| Added | Feb 2, 2016 |
| Latest | $5.60 Apr 16, '16 |
| Highest | $5.60 Apr 16, '16 |
| Lowest | $4.33 Mar 18, '16 |
| Average | $4.97 (30d avg) $4.98 (Lifetime average) |
| Added | Feb 2, 2016 |
| Latest | $0.01 Apr 16, '16 |
| Highest | $0.01 Feb 2, '16 |
| Lowest | $0.01 Feb 2, '16 |
| Average | $0.01 (30d avg) $0.01 (Lifetime average) |
| Added | Feb 2, 2016 |
30 day average: 457,948
Against a backdrop of virtual intercourse, online porn, and burgeoning Viagra sales, reveals how womens sexual difficulties are being repackaged as symptoms of a new disorder. In this compelling book, award-winning journalist Ray Moynihan teams up with drug assessment specialist Barbara Mintzes to investigate the creation of female sexual dysfunction or FSD, and the marketing machine that promises to "cure" it. The authors go inside the corridors of medical power to visit drug companysponsored scientific meetings and medical education events where doctors are being trained to see womens sexual problems as the symptoms of FSD a pharmaceutically treatable condition. Moynihan and Mintzes explore the underlying causes of sexual dissatisfaction among women and expose how global drug companies exploit those problems in an attempt to create the next billion dollar disease.